The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“another possible mechanism by which D-2-HG drives tumorigenesis is through the promotion of genetic instability, predisposing cells to oncogenic transformation103.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“Genomic studies have established that somatic mutations in IDH1 and IDH2 are perhaps the first genetic events to occur during tumorigenesis in human glioma and AML, and appear to initiate pathogenesis by a common mechanism103,115-117.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“The most commonly occurring cancers thought to arise from mutant IDH1/2 (mIDH1/2) include glioma, cartilaginous tumours, AML, angioimmunoblastic T cell lymphoma (AITL) and intrahepatic cholangiocarcinoma (ICC).”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citationComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Research works printed but not linked: 2
- Delahunt B, 1997, Mod Pathol, 10, 537
- Schmidt LS, 1998, Cancer Res, 58, 1719
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Inactivation of Epigenetic Regulators due to Mutations in Solid Tumors
Nemtsova, M. V., Mikhaylenko, D. S., Kuznetsova, E., Bykov, I. I., & Zamyatnin, A. A. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920070020 · Cited by 5
Mapping in vivo genetic interactomics through Cpf1 crRNA array screeningPreprint
Chow, R. D.-W., Wang, G., Codina, A., Ye, L., & Chen, S. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/153486 · Cited by 5
Pan-cancer machine learning predictors of primary site of origin and molecular subtypePreprint
Flynn, W. F., Namburi, S., Paisie, C. A., Reddi, H. V., Li, S., Karuturi, R. K. M., & George, J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/333914 · Cited by 5
Ball, M. W., & Ricketts, C. J. (2020) · Cancer · doi:10.1002/cncr.32915 · Cited by 5
Computational prediction of therapeutic response and cancer outcomesPreprint
Griffiths, M., Kubeyev, A., Laurie, J., Giorni, A., da Silva, L. A. Z., Sivasubramaniam, P., Foster, M. T., Biankin, A. V., & Asghar, U. S. (2024) · medRxiv · doi:10.1101/2024.01.17.24301444 · Cited by 5
Cancer target discovery enabled by transcriptome-based virtual CRISPR screeningPreprint
Sadagopan, A., Li, B., Li, J., Cui, Y., Deodhar, R., Yang, D., Wu, Y., Konda, P., Biji, C., Thapa, D. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.24.620074 · Cited by 5
Yanus, G. A., Iyevleva, A. G., Suspitsin, E. N., Tumakova, A. V., Белогубова, Е. В., Алексахина, С. Н., Togo, A. V., & Имянитов, Е. Н. (2023) · Sechenov Medical Journal · doi:10.47093/2218-7332.2023.14.2.5-20 · Cited by 4
Wiśniowski, T., Bryda, J., Domosud, J., & Wątroba, S. (2024) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/192555 · Cited by 4
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome
Mercken, K., Berkel, B. V., & Wever, L. D. (2024) · Journal of the Belgian Society of Radiology · doi:10.5334/jbsr.3687 · Cited by 4
Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Vento, J. A., Zhang, T., Kapur, P., Hammers, H. J., Brugarolas, J., & Qin, Q. (2025) · Cancers · doi:10.3390/cancers17091527 · Cited by 4
Liu, Y., Zhou, L., Dong, L., Wang, X., Ouyang, B., Xu, H., Wang, C., & Yang, X. (2025) · Histopathology · doi:10.1111/his.15512 · Cited by 4
A position-aware sets based weakly supervised framework for whole-slide subtype classification
Song, J., Yu, B., Liu, X., Cong, L., Zhou, Z., Cong, X., Sun, H., Pang, S., & Chen, H. (2025) · Engineering Applications of Artificial Intelligence · doi:10.1016/j.engappai.2025.111998 · Cited by 4
Yao, Z.-Y., Xing, C., Liu, Y., & Xing, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750997 · Cited by 4
CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway
Tian, P., Deng, J., Ma, C., Miershali, A., Maimaitirexiati, G., Yan, Q., Liu, Y., Maimaiti, H., Li, Y., Zhou, C., et al. (2023) · Oncology Letters · doi:10.3892/ol.2023.14147 · Cited by 4
Papillary Renal Cell Carcinoma: Current Evidence and Future Directions
Jang, A., Hobeika, C. S., & Gupta, S. (2024) · Kidney Cancer · doi:10.3233/kca-230027 · Cited by 4
Hwang, J., Bang, S., Choi, M. H., Hong, S., Kim, S. W., Lee, H., Yang, J., Park, U. S., & Choi, Y. J. (2024) · Cancers · doi:10.3390/cancers16112006 · Cited by 4
Ma, X., Chen, J., Chen, S., Lan, X., Wei, Z., Gao, H., & Hou, E. (2024) · Medicine · doi:10.1097/md.0000000000038991 · Cited by 4
Management of Metastatic Renal Cell Carcinoma with Variant Histologies
Flippot, R., Damarla, V. K., & McGregor, B. A. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.003 · Cited by 4
Li, C., Lu, Q., Huang, B., Wang, P., & Wang, W.-P. (2020) · Clinical Radiology · doi:10.1016/j.crad.2020.09.020 · Cited by 4
Tian, X., Xu, W., Wu, J., Gan, H., Wang, H., Gu, W., Qu, Y., Zhang, H., & Ye, D. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609809 · Cited by 4
Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma
Brown, J. R., Calaway, A. C., Castle, E. P., García, J., & Barata, P. C. (2022) · Kidney Cancer · doi:10.3233/kca-210005 · Cited by 4
Evolution in the Pathologic Classification of Renal Neoplasia
Alaghehbandan, R., Campbell, S. C., & McKenney, J. K. (2023) · Urologic Clinics of North America · doi:10.1016/j.ucl.2023.01.001 · Cited by 4
Comparison and validation of different risk models for papillary renal cell carcinoma
Lin, H., Sun, Q., Li, Z., Zheng, J., Zhang, X., Xiong, Y., Chen, H., Hou, Y., Xi, W., & Lin, J. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.05.017 · Cited by 4
Kidney Organoid Derived from Human Pluripotent and Adult Stem Cells for Disease Modeling
Kang, H. M. (2023) · Development & Reproduction · doi:10.12717/dr.2023.27.2.57 · Cited by 4
Geng, B., Liu, W., Wang, J., Zhang, W. Y., Li, Z., Zhang, N., Hou, W., Zhao, E., Li, X., & You, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1333507 · Cited by 4
Karpiński, P., Patai, Á. V., Hap, W., Kielan, W., Łaczmańska, I., & Sasiadek, M. M. (2018) · Epigenomics · doi:10.2217/epi-2018-0057 · Cited by 4
Stenman, M., Staehler, M. D., Szabados, B. E., Sandström, P., Laurell, A., Lindskog, M., & Harmenberg, U. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1537505 · Cited by 4
Somatic Substitution Signature as an Innovative Tool in Lung Cancer Diagnosis
Busca, S., Salleron, J., Boidot, R., Merlin, J., & Harlé, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-51155-3 · Cited by 4
Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges?
Mir, M. C., Albiges, L. K., Bex, A., Hora, M., Giannarini, G., Volpe, A., & Morgan Rouprêt, A. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.05.010 · Cited by 4
Kim, J., Jeong, H., Heo, D. S., Keam, B., Moon, K. C., Kwak, C. H., Jang, J., Kim, S., Kim, J., Lee, S., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3466 · Cited by 4
Graham, T. M., Stevens, T. M., & Gordetsky, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-92309-3_2 · Cited by 4
cMET: a prognostic marker in papillary renal cell carcinoma?
Erlmeier, F., Bruecher, B., Stöhr, C., Herrmann, E., Polifka, I., Agaimy, A., Trojan, L., Ströbel, P., Becker, F. O., Wülfing, C., et al. (2022) · Human Pathology · doi:10.1016/j.humpath.2021.12.007 · Cited by 4
Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers
Ellegate, J., Mastri, M., Isenhart, E., Krolewski, J. J., Chatta, G. S., KAUFFMAN, E. C., Moffitt, M. N., & Eng, K. H. (2022) · Cancers · doi:10.3390/cancers14030731 · Cited by 4
Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
Leone, A. R., Diorio, G., Zargar‐Shoshtari, K., & Spiess, P. E. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.03.21 · Cited by 4
Han, Y., Lu, S., Yu, F., Liu, X., Sun, H., Wang, J., Zhu, X., Lu, H., Yue, H., Wang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep37240 · Cited by 4
Zhang, X., Lu, X., Liu, Z., Guan, R., Wang, J., Kong, X., Chen, L., Bo, C., Tian, K., Xu, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32174 · Cited by 4
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2021) · Science Progress · doi:10.1177/00368504211010938 · Cited by 4
Thouvenin, J., Barthélémy, P., & Ladoire, S. (2020) · Bulletin du Cancer · doi:10.1016/s0007-4551(20)30279-4 · Cited by 4
Park, C., De, T., Xu, Y., Zhong, Y., Gamazon, E. R., Smithberger, E., Alarcon, C., & Perera, M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/491225 · Cited by 4
Hilser, T., Casuscelli, J., Aydogdu, C. D., Zschäbitz, S., Schnabel, M. J., Rinderknecht, E., Mattigk, A., Schostak, M., Volk, A.-L., Ivanyi, P., et al. (2025) · European Urology Open Science · doi:10.1016/j.euros.2025.06.011 · Cited by 3
Okada, H., Nasti, A., Sakai, Y., Takeshita, Y., Iwabuchi, S., Ho, T. T. B., Hashiba, T., Takata, N., Sato, T., Urabe, T., et al. (2025) · Genes · doi:10.3390/genes16091075 · Cited by 3
Chen, W., Tanaka, H., Yoshida, S., Matsumoto, S., Kobayashi, M., Fukuda, S., Fukushima, H., Waseda, Y., & Fujii, Y. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102458 · Cited by 3
Zhao, W., Demczyszyn, S. M., Coffey, N. J., Jiang, Y., Kim, B., Bowers, S., Bowman, C. E., Noji, M., Jang, C., Simon, M. C., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.182711 · Cited by 3
Castillo, V. F., Zakhary, A., Rotondo, F., Ciano‐Oliveira, C. D., Hamdani, M., Adona, E., van der Kwast, T., Trpkov, K., & Saleeb, R. (2025) · The Journal of Pathology · doi:10.1002/path.70001 · Cited by 3
Extrachromosomal circular miRNA-gene amplifications contribute to the renal cancer phenotype
Han, P., Lv, W., Xu, Z., Yu, T., Gao, S., Xiang, X., Pan, X., Zeng, Y., Havgaard, J. H., Gorodkin, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116660 · Cited by 3
Bouraoui, Y., Said, R., Bruß, C., Martowicz, A., Wagner, K., Weber, F., Engelmann, S. U., Kälble, S., Höring, M., Liebisch, G., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773666 · Cited by 3
Jackson‐Spence, F., Larkin, J., Patel, P., Valderrama, B. P., Rodríguez‐Vida, A., Glen, H., Thistlethwaite, F. C., Ralph, C., Srinivasan, G., Méndez-Vidal, M. J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01840 · Cited by 3
The role of precision medicine for the treatment of metastatic renal cell carcinoma
Ciccarese, C., Nunno, V. D., Montironi, R., Fiorentino, M., Brunelli, M., Tortora, G., Ardizzoni, A., & Massari, F. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1214057 · Cited by 3
Tang, Q., Pan, D., Xu, C., & Chen, L. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04482-4 · Cited by 3
Stage Migration in Renal Malignancies in COVID Era: A Single-Center Analysis
Gupta, A., Patil, A. P., Patel, D., Singh, A. G., Ganpule, A. P., Sabnis, R. B., & Desai, M. R. (2023) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-023-01771-3 · Cited by 3
Akkuş, E., Yekedüz, E., & Ürün, Y. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102314 · Cited by 3
Intra-clustering analysis reveals tissue-specific mutational patterns
Choudalakis, S., Kastis, G. A., & Δικαίος, Ν. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108681 · Cited by 3
Zheng, X., Liu, Y., Yang, Z., & Tian, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02401-w · Cited by 3
Histopathologie und Molekularpathologie des Nierenzellkarzinoms
Stöhr, C., Amann, K., & Hartmann, A. (2014) · Der Onkologe · doi:10.1007/s00761-014-2773-4 · Cited by 3
Non-clear-cell renal carcinoma therapy: handle with care
Buti, S., & Bersanelli, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00013-9 · Cited by 3
Mikhaylenko, D. S., Tanas, A. S., Zaletaev, D. V., & Nemtsova, M. V. (2020) · Journal of Oncology · doi:10.1155/2020/7363102 · Cited by 3
Advanced Non–Clear Cell Kidney Cancer
Ornstein, M. C., & Hutson, T. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000474 · Cited by 3
Zheng, B., Cheng, F., Yao, Z., Zhang, Y., Cong, Z., Wang, J., Niu, Z., & He, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818194 · Cited by 3
Differential Activation of NRF2 Signaling Pathway in Renal-Cell Carcinoma Caki Cell Lines
Hitefield, N. L., Mackay, S. S., Hays, L. E., Chen, S., Oduor, I. O., Troyer, D. A., & Nyalwidhe, J. O. (2023) · Biomedicines · doi:10.3390/biomedicines11041010 · Cited by 3
Erdem, S., Bertolo, R. G., Campi, R., Umberto Capitanio, A., Amparore, D., Anceschi, U., Mir, M. C., Roussel, E., Pavan, N., Carbonara, U., et al. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.01.028 · Cited by 3
Eule, C. J., Hu, J., Hedges, D. J., Jani, A. H., Pshak, T. J., Manley, B. J., Sánchez, A., Dreicer, R., Myint, Z. W., Zakharia, Y., et al. (2024) · Cancers · doi:10.3390/cancers16101920 · Cited by 3
The Role of Tumor‐Derived Extracellular Vesicles in Drug Resistance in Urologic Cancers
Xiong, Z., Chen, T., Wu, S., Deng, M., Wu, Q., Huang, D., He, C., Li, C., & Zheng, J. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400051 · Cited by 3
Özer, B., & Sezerman, O. U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171694 · Cited by 3
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma
Iacovelli, R., Cannella, M. A., Ciccarese, C., Astore, S., Foschi, N., Palermo, G., & Tortora, G. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1976147 · Cited by 3
New targeted therapies in kidney cancer
Mayrhofer, K., & Niedersüß‐Beke, D. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00782-6 · Cited by 3
Man, Y., Shang, X., Liu, C., Zhang, W. Y., Huang, Q., Ma, S., Shiang, R., Zhang, F., Zhang, L., & Zhang, Z. (2022) · Current Oncology · doi:10.3390/curroncol29040192 · Cited by 3
Xinyi, C. (2022) · International Conference on Bioinformatics and Computational Biology (ICBCB) · doi:10.1109/icbcb55259.2022.9802487 · Cited by 3
Shetty, K. S., Jose, A., Bani, M., & Vinod, P. K. U. (2023) · Molecular Genetics and Genomics · doi:10.1007/s00438-023-02022-4 · Cited by 3
Genetic characteristics of the non-clear cell renal cancer
Mikhaylenko, D. S., Alekseev, B. Y., Ефремов, Г. Д., & Каприн, А. Д. (2016) · Cancer Urology · doi:10.17650/1726-9776-2016-12-3-14-21 · Cited by 3
Molecular Genetics of Renal Cell Carcinoma
Fukawa, T., Shannon, N. B., Huang, D., Tan, J. Y., Yao, X., Rozen, S., Tan, P., & Teh, B. T. (2017) · Springer eBooks · doi:10.1007/978-4-431-55531-5_3 · Cited by 3
Taylor, A. S., & Skala, S. L. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.04.043 · Cited by 3
Immune checkpoint inhibitors in renal cell carcinoma
(2023) · Frontiers research topics · doi:10.3389/978-2-8325-2317-9 · Cited by 3
Exploiting the circuit breaker cancer evolution model in human clear cell renal cell carcinoma
Hsieh, J. J.-D., & Cheng, E. H. Y. (2020) · Cell Stress · doi:10.15698/cst2020.08.227 · Cited by 3
Zhan, X., Liu, Y., Yu, C. Y., Wang, T., Zhang, J., Ni, D., & Huang, K. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00827-5 · Cited by 3
Kidney Tumors Associated With Hereditary Cancer Syndromes
Mochel, M. C., & Smith, S. C. (2017) · AJSP Review and Reports · doi:10.1097/pcr.0000000000000220 · Cited by 3
Papillary Renal-Cell Carcinoma
Linehan, W. M., Merino, M. J., & Ricketts, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1601872 · Cited by 3
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View
Montironi, R., Gasparrini, S., Cimadamore, A., Roberta Mazzucchelli, A., Massari, F., Liang Cheng, C., Antonio Lopez-beltran, B., Moch, H., Montorsi, F., & Scarpelli, M. (2017) · European Urology Supplements · doi:10.1016/j.eursup.2017.08.008 · Cited by 3
Longer Telomere Length and Renal Cell Carcinoma
Casuscelli, J., & Hakimi, A. A. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.008 · Cited by 3
Genomic Strategies for Personalized Cancer Therapy
Dudek, A. Z., Baxstrom, K., Bharadwaj, S., Blaes, A. H., Kulkarni, A. A., Lou, E., Nehru, V. M., Rabinovich, E., Shergill, A. P., & Viner, M. (2020) · Wiley eBooks · doi:10.1002/9781119432487.ch1 · Cited by 3
Gupta, S. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.011 · Cited by 3
Wang, Y., Xu, G., Yang, H., Zhou, X. A., & Wen, H. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.08.008 · Cited by 2
Runarsson, T. G., Bergmann, A., Erlingsdóttir, G., Pétursdóttir, V., Heitmann, L. A., Johannesson, A., Asbjornsson, V., Axelsson, T., Hilmarsson, R., & Guðbjartsson, T. (2024) · BMC Urology · doi:10.1186/s12894-024-01494-9 · Cited by 2
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma
Konda, P., Wakolbinger, A. J., Cui, Y., Oliveira, G. R. D., Laimon, Y. N., Weiss, C. N., Seager, M. D., Deodhar, R., Li, J., Matar, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76858-w · Cited by 2
DNA Methylation-Based Classification of Kidney Neoplasms
Papanicolau‐Sengos, A., Singh, O., Park, K., Snuderl, M., Tretiakova, M., Merino, M., Stohr, B. A., Simko, J. P., Deng, F.-M., Chan, E., et al. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100884 · Cited by 2
Vissers, J. H. A., Mitchell, C., Prall, O. W. J., Lo, W., Kanwal, S., Luen, S. J., Watts, S. C., Angel, C. M., Khoo, C., Pang, J., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01534-5 · Cited by 2
Aljahdali, I. A. M., Ling, X., Wu, W., Wang, W., Li, D., Zhang, R., Zhang, E., Stablewski, A. B., Azrak, R. G., Li, Q., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03547-9 · Cited by 2
The evolution of renal cell carcinoma classification
Pan, C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001311 · Cited by 2
Wang, W., Zhao, D., Zhou, Z., Chen, B., Zhang, C., Du, E., & Zhang, L. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1755318 · Cited by 2
Ishihara, H., Liu, Y.-Y., Yamashita, R., Fukuda, H., Mizoguchi, Y., Yamashita, M., Kitano, S., Aoki, K., Tachibana, H., Mizoguchi, S., et al. (2026) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0939 · Cited by 2
McCarthy, M., Wojcik, A. A., Fritcher, E. G. B., Tekin, B., Shen, W., Al‐Kateb, H., Dasari, S., Lucas, P. C., Ebare, K., REYNOLDS, J. P., et al. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.11.003 · Cited by 2
Jixiang, B., Chen, X., Xiaoxuan, P., Mingli, S., Jieru, H., & Shuhui, W. (2026) · Discover Oncology · doi:10.1007/s12672-026-04707-9 · Cited by 2
Liu, X., Chen, Y., Liu, W., Pan, J., Liu, J., Dong, X., Ma, W., Feng, F., Liu, N., Xu, J., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.04.012 · Cited by 2
Gupta, S., Sterner, R. M., Hasumi, H., Jikuya, R., Nakagawa, H., Kryvenko, O. N., Jordà, M., Torell, N. R., Stander, Z., Colef, R. G., et al. (2026) · Human Pathology · doi:10.1016/j.humpath.2026.106205 · Cited by 2
Biomarkers as Putative Therapeutic Targets in Colorectal Cancer
Pal, S., Garg, M., & Pandey, A. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-63369-1_8 · Cited by 2
Takamori, H., Maeshima, A. M., Kato, I., Baba, M., Nakamura, E., & Matsui, Y. (2023) · IJU Case Reports · doi:10.1002/iju5.12575 · Cited by 2
Androgen Receptor and Non-Coding RNAs’ Interaction in Renal Cell Carcinoma
Hussain, M. A., Elemam, N. M., & Talaat, I. M. (2024) · Non-Coding RNA · doi:10.3390/ncrna10060056 · Cited by 2
Exploiting NRF2 ‐ ARE pathway activation in papillary renal cell carcinoma
Angori, S., Lakshminarayanan, H., Banaei‐Esfahani, A., Mühlbauer, K., Bolck, H. A., Kallioniemi, O., Pietiäinen, V., Schraml, P., & Moch, H. (2024) · International Journal of Cancer · doi:10.1002/ijc.35311 · Cited by 3
Kessler, C., von Brandenstein, M., Klümper, N., Krausewitz, P., Storz, E., Rieger, C., Sperber, L., Paffenholz, P., Tolkach, Y., Nestler, T., et al. (2025) · World Journal of Urology · doi:10.1007/s00345-025-05880-2 · Cited by 2
Is Tubulocystic Renal Cell Carcinoma Real?
Ding, Y., Miyamoto, H., & Rothberg, P. G. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.10.004 · Cited by 2
Bonadio, R. C., Velho, P. I., Marta, G. N., Narda, M., Souza, M. C. L. A., Muniz, D. Q. B., Bezerra, R. O. F., Bispo, R. K., Faraj, S. F., Bastos, D. A., et al. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.973 · Cited by 2
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-14
- Volume
- 374
- Issue
- 2
- Pages
- 135-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4775252
- OpenAlex
- W2111867681
- Cited by
- 1,336
- References
- 42
- Citations by year
- 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
- FWCI
- 92.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
- MeSH terms
- Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
